AWA
CBAY

Amplius Wealth Advisors’s Cymabay Therapeutics CBAY Stock Holding History

Amplius Wealth Advisors’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-550
Closed -$1K – 975
2021
Q4 		$1K Buy
+550
New +$2.09K ﹤0.01% 928

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Amplius Wealth Advisors's CBAY Position: Q1 2022 in Review

Amplius Wealth Advisors sold out of Cymabay Therapeutics (CBAY) in Q1 2022, closing a stake of 550 shares — an estimated $1K sold.

Amplius Wealth Advisors first reported a position in CBAY in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 118 funds tracked by Wall St. Rank hold CBAY as of Q1 2022.

  • Amplius Wealth Advisors reported no remaining Cymabay Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Amplius Wealth Advisors sold 550 Cymabay Therapeutics shares in Q1 2022, an estimated $1K.
  • Amplius Wealth Advisors first reported a position in Cymabay Therapeutics in Q4 2021 and held it in 1 quarter.
  • Amplius Wealth Advisors's Cymabay Therapeutics position peaked at $1K in Q4 2021.
  • 118 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2022.

Based on Amplius Wealth Advisors's 13F filing for Q1 2022, filed 9 May 2022.